Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 3/20 | 0.69 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578852 | 0.97 | FASN (0.69) | FASNPLA2G2APLA2G5IMPDH2FFAR1 | |
| SCHEMBL31232367 | 0.92 | FASN (0.59) | FASNPLA2G2APLA2G5IMPDH2FFAR1 | |
| SCHEMBL30550331 | 0.92 | FASN (0.59) | FASNPLA2G2APLA2G5IMPDH2FFAR1 | |
| SCHEMBL30151487 | 0.90 | FASN (0.77) | FASNPLA2G2APLA2G5IMPDH2FFAR1 | |
| SCHEMBL34468635 | 0.88 | FASN (0.55) | FASNPLA2G2APLA2G5IMPDH2 | |
| SCHEMBL7530367 | 0.87 | FASN (0.64) | FASNPLA2G2APLA2G5IMPDH2FFAR1 | |
| SCHEMBL30898483 | 0.87 | FASN (0.53) | FASNPLA2G2APLA2G5IMPDH2FFAR1 | |
| SCHEMBL29720143 | 0.87 | FASN (0.53) | FASNPLA2G2APLA2G5IMPDH2FFAR1 | |
| SCHEMBL31578934 | 0.86 | FASN (0.52) | FASNPLA2G2AKCNA3ABCB1ALDH1A1 | |
| SCHEMBL34468687 | 0.86 | FASN (0.52) | FASNPLA2G2APLA2G5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250162973-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | University of Hong Kong Versitech Limited (CN) | 2025-05-22 | — | — | US | disclosed |
| WO-2023160543-A9 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | VERSITECH LIMITED (CN) | 2024-09-26 | — | — | WO | disclosed |
| WO-2023160543-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | VERSITECH LIMITED (CN) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250162973-A1 | METHODS OF SYNTHESIS AND USES OF AGRIMOL COMPOUNDS | GOLIM4, GOLT1B, GOLGA2 | FASN 1842/4885PLA2G2A 1194/4885PLA2G5 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.